Host Immune Response to Clostridium Difficile Infection (ICD)
- Conditions
- Diarrhea Due to Clostridium Difficile
- Interventions
- Biological: Blood sampling
- Registration Number
- NCT02440438
- Lead Sponsor
- Hospices Civils de Lyon
- Brief Summary
Clostridium difficile is responsible for up to 25% of reported antibiotic associated diarrhea cases and virtually all cases of pseudomembranous colitis (PMC). The clinical spectrum of C. difficile infection (CDI) varies in severity from asymptomatic carriage to self-limited, mild, watery diarrhea, to PMC, intestinal perforation, toxic megacolon, sepsis, fulminant colitis, and death. In the past decade, the 027/NAP1/BI strain has emerged world-wide and has been implicated in large outbreaks with increased severity, frequent recurrence, and significant mortality. The host immune responses can influence the severity of CDI and play crucial roles in CDI onset, progression, and overall prognosis. Low serum concentrations of antibodies directed against the toxins A\&B of C. difficile have been associated with a higher risk of recurrence. However, there are conflicting reports.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 56
- Hospitalized
- Suffering from diarrhea related to C. difficile
- Confirmed diagnosis of CDI
- Informed consent by the patient
- Affiliated to the social security regime
- Out-patient
- No confirmed diagnosis of CDI
- Decline of participation
- Patient not affiliated to the social security regime
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description Clostridium difficile infection Blood sampling -
- Primary Outcome Measures
Name Time Method immune response rate up to 60 days after diagnosis
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
Service d'Hygiène, Epidémiologie et Prévention - Hôpital Edouard Herriot
🇫🇷LYON cedex 03, France